Headlines

Biogen (BIIB) says Phase 2 CELIA data presented at AAIC demonstrate meaningful clinical outcomes and robust tau reduction with diranersen in early Alzheimer’s disease

Newsquawk Staff ·

Biogen (BIIB) says Phase 2 CELIA data presented at AAIC demonstrate meaningful clinical outcomes and robust tau reduction with diranersen in early Alzheimer’s disease.

Related headlines